Intra-Cellular Therapies Q4 2023 GAAP EPS $(0.30) Beats $(0.45) Estimate, Total Revenues $132.10M Miss $135.67M Estimate
Portfolio Pulse from Benzinga Newsdesk
Intra-Cellular Therapies (ITCI) reported Q4 2023 earnings with a GAAP EPS of $(0.30), surpassing the $(0.45) estimate. However, their total revenues of $132.10M fell short of the $135.67M estimate, marking a 50.34% increase from the previous year.
February 22, 2024 | 12:32 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Intra-Cellular Therapies reported better-than-expected Q4 2023 EPS but missed revenue estimates, with a significant year-over-year sales increase.
The mixed results with an EPS beat but a slight miss on revenue forecasts could lead to a neutral short-term impact on ITCI's stock price. The significant year-over-year sales growth is positive, but the revenue miss may temper investor enthusiasm.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100